title: (18)F-FDG PET/CT imaging of squamous cell carcinoma induced by Vemurafenib.
authors.affiliation: Department of Radiology, Mayo Clinic, Scottsdale, AZ, United States. Electronic address: nguyen.ba@mayo.edu.
authors.forename: B D
authors.initials: BD
authors.lastname: Nguyen
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced / Q000000981:diagnostic imaging* / Q000209:etiology; D003131:Combined Modality Therapy; D057915:Drug Substitution; D005121:Extremities; D005462:Fluorine Radioisotopes / Q000032:analysis; D019788:Fluorodeoxyglucose F18 / Q000032:analysis; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D000074324:Ipilimumab; D008113:Liver Neoplasms / Q000188:drug therapy / Q000601:surgery; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary / Q000601:surgery; D009381:Neoplasms, Radiation-Induced / Q000139:chemically induced / Q000000981:diagnostic imaging* / Q000209:etiology; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000000981:diagnostic imaging* / Q000209:etiology; D000072078:Positron Emission Tomography Computed Tomography; D011836:Radiation Tolerance / Q000187:drug effects; D019275:Radiopharmaceuticals / Q000032:analysis; D012074:Remission Induction; D012878:Skin Neoplasms / Q000139:chemically induced / Q000000981:diagnostic imaging* / Q000209:etiology; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use; D013472:Sunlight / Q000009:adverse effects; D000077484:Vemurafenib
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D005462:Fluorine Radioisotopes; D007211:Indoles; D000074324:Ipilimumab; D019275:Radiopharmaceuticals; D013449:Sulfonamides; D019788:Fluorodeoxyglucose F18; D000077484:Vemurafenib